Thymopentin treatment in AIDS and pre-AIDS patients. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Thymopentin treatment in AIDS and pre-AIDS patients.

Surv Immunol Res. 1985;4 Suppl 1:58-62. Unique Identifier : AIDSLINE MED/85299994
Clumeck N; Cran S; Van de Perre P; Mascart-Lemone F; Duchateau J; Bolla K

Abstract: Three pilot studies testing thymopentin in AIDS patients are presented. One study included 5 patients with the full-blown syndrome, all treated with 50 mg thymopentin 3 times a week by intravenous slow infusion; no immunologically nor clinically positive results were observed, indicating that the T cell pool in such patients is severely depleted. Six other patients with the prodromal stage of AIDS were treated 1 month with 50 mg thymopentin administered as an intravenous bolus injection 3 times weekly and thereafter for another month with same dose regimen as intravenous slow infusions. The patients on infusion therapy experienced statistically significant immunological improvements; these positive findings were paralleled with an improvement of the patients' clinical condition. These positive responses persisted for an average of 8 months. In another group of 5 pre-AIDS patients thymopentin was administered via the subcutaneous route using 15 mg 3 times weekly; only 1 patient revealed immunological and clinical improvement. In summary, only patients with the pre-AIDS syndrome are likely to benefit from immunomodulation therapy with thymopentin, and the mode of administration seems to be crucial.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/IMMUNOLOGY Adjuvants, Immunologic/THERAPEUTIC USE Human In Vitro Lymphocyte Transformation/DRUG EFFECTS Peptide Fragments/*THERAPEUTIC USE Phytohemagglutinins/PHARMACOLOGY T-Lymphocytes/CLASSIFICATION/DRUG EFFECTS/IMMUNOLOGY Thymopoietins/*THERAPEUTIC USE Thymus Hormones/*THERAPEUTIC USE JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDdrugtherapy/immunologyadjuvants,immunologic/therapeuticusehumaninvitrolymphocytetransformation/drugeffectspeptidefragments/KWDtherapeuticusephytohemagglutinins/pharmacologyt-lymphocytes/classification/drugeffects/immunologythymopoietins/KWDtherapeuticusethymushormones/KWDtherapeuticusejournalarticle
851230
M85C0137

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .